---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-000752"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:39:01.408680+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics licenses Mayo Clinic's PSMA Alpha-PET platform for up to $68M milestones

## Summary
- Upfront cash payment of $1M due within 60 days of Dec 22, 2023; milestone payments up to $68M tied to clinical, regulatory, and commercialization achievements.
- Single-digit royalties on net sales of certain Licensed Product components; 40% of any PRV sale proceeds to be shared with Mayo.
- Platform uses 64/67 Cu and 203/212 Pb double chelator design for PET imaging and alpha/beta-particle targeted RPT.
- Preclinical data showed favorable salivary gland uptake and kidney clearance vs. comparators; initial focus on PSMA-expressing prostate cancer.
- Mayo Clinic holds financial interest in the technology; Perspective must use commercially reasonable efforts to bring Licensed Products to market.

## SEC filing metadata
- accession: 0001437749-24-000752
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774924000752/0001437749-24-000752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774924000752/isr20240104_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-000752
- JSON: https://secwatch.observer/filing/0001437749-24-000752.json
- Plain text: https://secwatch.observer/filing/0001437749-24-000752.txt

## Key facts
- Material Agreements
  Perspective Therapeutics, Inc. entered into Exclusive Patent License Agreement with Mayo Foundation for Medical Education and Research valued at upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s (effective 2023-12-31).
  - Action: entry
  - Agreement: license
  - Counterparty: Mayo Foundation for Medical Education and Research
  - Value: upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s
  - Effective: 2023-12-31
  source text: On December 31, 2023, Perspective Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an exclusive patent license agreement (the “ License Agreement ”) with the Mayo Foundation for Medical Education and Research (“ Mayo Clinic ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774924000752/0001437749-24-000752-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.